Repligen (NASDAQ:RGEN) Updates FY 2024 Earnings Guidance

Repligen (NASDAQ:RGEN) issued an update on its FY 2024 earnings guidance on Tuesday morning. The company provided earnings per share guidance of 1.500-1.580 for the period, compared to the consensus earnings per share estimate of 1.430. The company issued revenue guidance of $630.0 million-$639.0 million. Repligen also updated its FY24 guidance to $1.50-1.58 EPS.

Repligen Stock Down 6.2 %

NASDAQ:RGEN traded down $8.88 on Friday, reaching $133.55. 136,573 shares of the stock traded hands, compared to its average volume of 657,876. The company has a market capitalization of $7.48 billion, a price-to-earnings ratio of -361.50, a PEG ratio of 4.36 and a beta of 0.96. The company has a current ratio of 6.65, a quick ratio of 5.56 and a debt-to-equity ratio of 0.26. Repligen has a 12 month low of $113.50 and a 12 month high of $211.13. The company’s fifty day simple moving average is $141.59 and its 200 day simple moving average is $144.78.

Repligen (NASDAQ:RGEN) last released its quarterly earnings data on Tuesday, November 12th. The biotechnology company reported $0.43 earnings per share for the quarter, beating analysts’ consensus estimates of $0.34 by $0.09. The business had revenue of $154.87 million during the quarter, compared to analyst estimates of $153.34 million. Repligen had a negative net margin of 3.36% and a positive return on equity of 3.92%. Repligen’s revenue was up 9.7% compared to the same quarter last year. During the same period last year, the business earned $0.23 EPS. Equities analysts predict that Repligen will post 1.44 EPS for the current fiscal year.

Wall Street Analyst Weigh In

RGEN has been the topic of a number of recent analyst reports. Wolfe Research initiated coverage on shares of Repligen in a report on Thursday. They set a “peer perform” rating on the stock. Stephens restated an “overweight” rating and issued a $170.00 price target on shares of Repligen in a research note on Tuesday, July 30th. Benchmark reiterated a “hold” rating on shares of Repligen in a research report on Monday, August 5th. Wells Fargo & Company began coverage on Repligen in a research report on Tuesday, August 27th. They issued an “overweight” rating and a $180.00 target price on the stock. Finally, UBS Group reduced their price target on shares of Repligen from $205.00 to $185.00 and set a “buy” rating for the company in a research report on Wednesday, July 31st. Four research analysts have rated the stock with a hold rating and eight have given a buy rating to the company. According to MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $190.25.

Insider Activity

In related news, Director Anthony Hunt sold 22,191 shares of the business’s stock in a transaction that occurred on Tuesday, September 10th. The stock was sold at an average price of $145.37, for a total value of $3,225,905.67. Following the transaction, the director now directly owns 139,840 shares of the company’s stock, valued at approximately $20,328,540.80. The trade was a 13.70 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Insiders own 1.20% of the company’s stock.

Repligen Company Profile

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.